Výsledky vyhledávání - "E.M. Van rooijen"

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer

Autor: A.J. ten Tije, M Franken, E.M. van Rooijen, B.C. Tanis, Linda Mol, Miriam Koopman, C.A. Uyl-de Groot, Anne M. May, C.J.A. Punt, G.J.M. Creemers, A.M.T. van der Velden, M. G. H. van Oijen, Hendrik Koffijberg, H. van Tinteren

Publikováno v: European journal of cancer (Oxford, England, 75, 204-212. Elsevier Limited
European Journal of Cancer, 75, 204-212. Elsevier Ltd.
European Journal of Cancer, 75, 204. Elsevier Limited

Aim Capecitabine and bevacizumab (CAP-B) maintenance therapy has shown to be more effective compared with observation in metastatic colorectal cancer patients achieving stable disease or better after six cycles of first-line capecitabine, oxaliplatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a56c69a66a6cdca321f65ce68b666f3
https://dspace.library.uu.nl/handle/1874/350448

Zobrazit plný text záznamu

Diagnoses-based cost groups in the Dutch risk-equalization model: The effects of including outpatient diagnoses

Autor: E.M. van Rooijen, R. C. van Kleef, R.C.J.A. van Vliet

Publikováno v: Health Policy, 115(1), 52-59. Elsevier Ireland Ltd

Background: The Dutch basic health-insurance scheme for curative care includes a risk equalization model (RE-model) to compensate competing health insurers for the predictable high costs of people in poor health. Since 2004, this RE-model includes th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c839e75ac3c12bb454324d4f3b0d4a
https://pure.eur.nl/en/publications/f58fd963-8cae-4993-b31f-6960da3a064c

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání